The Chemours Company (CC) short interest & options flow
NYSECC: Mizuho downgraded CC to Neutral from Outperform, cutting its price target to $15.00 from $18.00, a 16.7% reduction. The stock closed at $13.20 on October 13, trading 12% below the new target. Analyst John Roberts cited weakening demand and TiO2 margin pressures despite the company's cost-reduction initiatives under its "Pathway to Thrive" program. The downgrade marks the latest in a string of target cuts from Wall Street over recent months, with the consensus price target now at $16.90 and the consensus rating holding at Hold. Short interest remains elevated at 10.2% of free float, though cost to borrow sits at just 0.52%, reflecting ample share availability for lending.
CC Mizuho downgrade to Neutral, price target cut to $15 from $18.
CC: Mizuho downgraded CC to Neutral from Outperform, cutting its price target to $15.00 from $18.00, a 16.7% reduction. The stock closed at $13.20 on October 13, trading 12% below the new target. Analyst John Roberts cited weakening demand and TiO2 margin pressures despite the company's cost-reduction initiatives under its "Pathway to Thrive" program. The downgrade marks the latest in a string of target cuts from Wall Street over recent months, with the consensus price target now at $16.90 and the consensus rating holding at Hold. Short interest remains elevated at 10.2% of free float, though cost to borrow sits at just 0.52%, reflecting ample share availability for lending.
- Market cap
- $2.08B
- Next earnings
- 19 Feb 2027
Key data as of 5 Nov 2026
Latest signals on CC
- Analyst
CC Mizuho downgrade to Neutral, price target cut to $15 from $18.
CC news and analysis
RSSNo long-form analysis yet for CC. Pulse alerts and the live data picture are available on ORTEX.
Open CC on ORTEX →Want the live picture for CC?
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CC — free to start on ORTEX.
Sign up for free →Open CC on ORTEX